<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00073554</url>
  </required_header>
  <id_info>
    <org_study_id>HA002</org_study_id>
    <secondary_id>NAPA-1</secondary_id>
    <nct_id>NCT00073554</nct_id>
  </id_info>
  <brief_title>Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion</brief_title>
  <official_title>A Phase 2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Activity of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCA Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Decisions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCA Biopharma, Inc.</source>
  <brief_summary>
    <textblock>
      This trial is for patients with acute occlusion of one of the arteries supplying blood to the
      leg. The trial is designed to determine the safety and activity of a novel clot dissolving
      (thrombolytic) drug (alfimeprase).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>100</enrollment>
  <condition>Arterial Occlusive Diseases</condition>
  <condition>Peripheral Vascular Diseases</condition>
  <condition>Thrombosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfimeprase</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Patients with acute peripheral arterial occlusion of the lower limb (onset of symptoms
             within 14 days)

          -  Rutherford Class I or IIa (minimal sensory loss, no muscle weakness, audible venous
             flow)

          -  Age 18 or above

          -  Able to consent

          -  Able to follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Toombs CF. Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis. Haemostasis. 2001 May-Dec;31(3-6):141-7. Review.</citation>
    <PMID>11910179</PMID>
  </reference>
  <verification_date>November 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2003</study_first_submitted>
  <study_first_submitted_qc>November 25, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2003</study_first_posted>
  <last_update_submitted>December 16, 2009</last_update_submitted>
  <last_update_submitted_qc>December 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

